DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.59 (2013)  >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/370

Files in This Item:

File Description SizeFormat
FksmJMedSci_59_p69.pdf334.28 kBAdobe PDFDownload
Title: Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension
Authors: Ono, Yoshiaki
Mizuno, Kenji
Takahashi, Michihiko
Miura, Yukio
Watanabe, Tsuyoshi
Affiliation: 生態・機能学領域
腎臓高血圧・糖尿病内分泌代謝内科学講座
Source title: Fukushima Journal of Medical Science
Volume: 59
Issue: 2
Start page: 69
End page: 75
Issue Date: 2013
Abstract: Objective: This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH).Methods: Urinary excretion of pyrraline (PR), pentosidine (PT), acrolein (AC), and 8-hydroxy-2'-deoxyguanosine (8-OH-dG) and microalbuminuria were assessed in patients with DM complicated by EH who were treated with candesartan 4 mg/day for 3 months.Results: In a total of 25 patients urinary excretion of PR (nmol/g· cr), PT (pmol/g· cr), and 8-OH-dG (ng/mg· cr) was significantly (all P < 0.05) decreased from (mean ± SEM) 11.9 ± 1.9, 30.6 ± 2.4, and 7.9 ± 0.6, respectively, at baseline to 8.4 ± 1.4, 27.1 ± 2.0, and 6.9 ± 0.6, respectively, at 3 months. Meanwhile, excretion of AC was unaltered from 209.6 ± 40.0 to 189 ± 24.8 nmol/mgcr (P = NS). Urinary albumin excretion was significantly (P < 0.05) reduced from 27.7 ± 4.6 to 14.1 ± 1.1 mg/g· cr. There were weak but statistically significant positive correlations between the change of urinary 8-OH-dG excretion and that of albumin (r = 0.414; P < 0.05) and change of hemoglobin (Hb) A1c (r = 0.45; P < 0.05).Conclusion: Candesartan exerts protective effect(s) on the cardiovascular system by suppression of oxidative stress-mainly through inhibiting production of advanced glycation end products (AGEs) rather than of advanced lipoxidation end products (ALEs)-in type 2 DM patients with EH.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/370
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/370/1/FksmJMedSci_59_p69.pdf
ISSN: 0016-2590
2185-4610
DOI: 10.5387/fms.59.69
PubMed ID: 24500381
Related Page: http://dx.doi.org/10.5387/fms.59.69
Rights: © 2013 The Fukushima Society of Medical Science
Appears in Collections:Vol.59 (2013)

Files in This Item:

File Description SizeFormat
FksmJMedSci_59_p69.pdf334.28 kBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard